Regenxbio (RGNX) Downgraded by ValuEngine

ValuEngine downgraded shares of Regenxbio (NASDAQ:RGNX) from a strong-buy rating to a buy rating in a research note published on Friday, ValuEngine reports.

RGNX has been the subject of several other research reports. BidaskClub lowered shares of Regenxbio from a hold rating to a sell rating in a research note on Thursday, May 2nd. Zacks Investment Research upgraded shares of Regenxbio from a hold rating to a buy rating and set a $51.00 price objective for the company in a research note on Tuesday, January 22nd. Finally, Raymond James upgraded shares of Regenxbio from an outperform rating to a strong-buy rating and set a $94.00 price objective for the company in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $78.72.

NASDAQ RGNX opened at $45.80 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.21 and a quick ratio of 15.24. The company has a market cap of $1.69 billion, a P/E ratio of 19.24 and a beta of 0.37. Regenxbio has a 52 week low of $38.56 and a 52 week high of $85.10.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.04). The firm had revenue of $0.88 million for the quarter. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. Research analysts forecast that Regenxbio will post -3.18 earnings per share for the current fiscal year.

In other Regenxbio news, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $53.23, for a total transaction of $266,150.00. Following the transaction, the senior vice president now owns 6,547 shares in the company, valued at approximately $348,496.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $47.29, for a total transaction of $709,350.00. Following the transaction, the chief executive officer now owns 261,000 shares in the company, valued at approximately $12,342,690. The disclosure for this sale can be found here. Insiders have sold a total of 70,368 shares of company stock worth $3,793,446 in the last 90 days. 13.80% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the business. Berman Capital Advisors LLC acquired a new position in Regenxbio during the 4th quarter valued at approximately $33,000. NumerixS Investment Technologies Inc acquired a new position in Regenxbio during the 4th quarter valued at approximately $50,000. Mckinley Capital Management LLC Delaware increased its stake in Regenxbio by 51.8% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 303 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new position in Regenxbio during the 1st quarter valued at approximately $55,000. Finally, PNC Financial Services Group Inc. increased its stake in Regenxbio by 568.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,190 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 1,012 shares in the last quarter. Institutional investors and hedge funds own 82.64% of the company’s stock.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: Why is the ex-dividend date different from the record date?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.